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and Dao Wen WangAbstract
Background: Recently, plasma miRNAs have been reported as biomarkers for various diseases. However, the
knowledge on the association of plasma miRNAs with ischemic stroke is still lacking. In this study, we investigated
whether plasma concentrations of miR-30a, miR-126 and let-7b may be biomarkers for ischemic stroke in humans.
Methods: One hundred ninety seven patients with ischemic stroke were recruited and their blood samples were
collected at 24 h, 1 week, 4 weeks, 24 weeks and 48 weeks after symptoms onset, and fifty healthy volunteers were
selected as control. Levels of miRNA were quantified by quantitative real-time PCR. Relative expression level of
miRNA was calculated using 2-ΔΔct method. The ability to distinguish the ischemic stroke group from control
group was characterized by receiver operating characteristic (ROC) curve, and the area under ROC curve (AUC)
was calculated.
Results: Circulating miR-30a and miR-126 levels were markedly down-regulated in all patients with ischemic stroke
until 24 weeks. However, circulating let-7b was lower in patients with large-vessel atherosclerosis than healthy
volunteers, whereas circulating let-7b had higher level in patients with other kinds of ischemic stroke until 24 weeks.
Among all patients, circulating miRNAs levels returned to normal 48 weeks after symptom onset. Receiver operating
characteristic (ROC) curve analysis showed that the areas under the curve (AUC) of plasma miR-30a were 0.91, 0.91, 0.92
and 0.93, the miR-126 were 0.92, 0.94, 0.93 and 0.92, and let-7b were 0.93, 0.92, 0.92 and 0.91 at 24 h, 1 w, 4 w and
24 w, respectively.
Conclusions: These data suggest that miR-30a, miR-126 and let-7b might be useful biomarkers for ischemic stroke in
humans.
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Stroke is a leading cause of death and long-term disability
in developed countries, and ~80% of strokes are ischemic
in origin [1]. In China, 2.5 million people have stroke and
1 million die from stroke-related causes every year [2].
Multiple risk factors for stroke include advanced age, dia-
betes mellitus, hypercholesterolemia, hypertension, alco-
hol, smoking etc. [3].
MicroRNAs (miRNAs) are a novel family of non
protein-coding short RNA molecules that regulate gene
expression by recognizing binding sites located in the 3′* Correspondence: chenchen@tjh.tjmu.edu.cn
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reproduction in any medium, provided the oruntranslated region (3′ UTR) of mRNA targets [4,5].
MiRNAs participate in a large number of physiological
and pathological processes, such as differentiation, de-
velopment, proliferation, apoptosis and migration [6-8].
However, compared with oncology or cardiology re-
searches, a few studies have investigated the roles of
miRNAs in neuronal death, degeneration or ischemic
stroke [9-11]. For instance, progressive neurodegenera-
tion occurs in the absence of Dicer, which is the crucial
regulator of miRNA biogenesis, and miR-8 targets atro-
phin to prevent neurodegeneration in Drosophila [12].
The miR-146aG allele and miR-146aG/-149 T/-196a2C/-
499G allele combinations were found to be associated
with ischemic stroke pathogenesis [13]. MicroRNA-195td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical characteristics of patients
CHS Age (YEARS) M/F CS (%) TC TG HDL LDL SBP DBP DM HT (%) HL (%) P
Stroke (24 h)
LA (n = 10) 62 ± 7 5/5 2 (20%) 4.48 ± 0.71 1.53 ± 0.43 1.13 ± 0.18 2.53 ± 0.58 132 ± 12 84 ± 13 1 (10%) 2 (20%) 2 (20%) 0.12
SA (n = 9) 63 ± 6 4/5 2 (22%) 4.32 ± 0.63 1.43 ± 0.23 1.24 ± 0.16 2.42 ± 0.61 125 ± 10 82 ± 14 2 (22%) 2 (22%) 1 (11%) 0.32
CEmb (n = 9) 64 ± 5 5/4 1 (11%) 4.18 ± 0.52 1.23 ± 0.18 1.02 ± 0.12 2.43 ± 0.47 130 ± 12 85 ± 11 1 (11%) 1 (11%) 1 (11%) 0.46
UDN (n = 10) 61 ± 6 5/5 2 (20%) 4.23 ± 0.34 1.36 ± 0.33 1.25 ± 0.27 2.45 ± 0.45 135 ± 13 80 ± 13 1 (10%) 2 (20%) 2 (20%) 0.78
Stroke (1 W)
LA (n = 11) 65 ± 6 5/6 2 (18%) 4.12 ± 0.25 1.54 ± 0.46 1.15 ± 0.12 2.50 ± 0.35 128 ± 14 82 ± 10 1 (9%) 2 (18%) 2 (20%) 0.98
SA (n = 10) 66 ± 4 5/5 2 (20%) 4.16 ± 0.32 1.44 ± 0.35 1.10 ± 0.17 2.43 ± 0.42 138 ± 27 86 ± 14 1 (10%) 2 (20%) 1 (10%) 0.54
CEmb (n = 11) 62 ± 7 6/5 2 (18%) 4.31 ± 0.17 1.32 ± 0.38 1.15 ± 0.14 2.46 ± 0.38 137 ± 10 85 ± 13 1 (9%) 1 (9%) 1 (9%) 0.65
UDN (n = 10) 63 ± 7 4/6 2 (20%) 4.42 ± 0.54 1.42 ± 0.43 1.17 ± 0.12 2.35 ± 0.36 132 ± 15 87 ± 11 1 (10%) 1 (10%) 1 (10%) 0.98
Stroke (4 W)
LA (n = 10) 65 ± 5 6/4 2 (20%) 4.39 ± 0.47 1.55 ± 0.39 1.18 ± 0.13 2.62 ± 0.56 130 ± 12 88 ± 10 1 (10%) 2 (20%) 2 (20%) 0.82
SA (n = 10) 64 ± 7 4/6 1 (10%) 4.36 ± 0.52 1.36 ± 0.36 1.09 ± 0.13 2.43 ± 0.34 129 ± 16 85 ± 11 2 (20%) 2 (20%) 1 (10%) 0.12
CEmb (n = 10) 63 ± 7 5/5 2 (20%) 4.26 ± 0.17 1.38 ± 0.29 1.12 ± 0.17 2.43 ± 0.33 130 ± 12 86 ± 10 1 (10%) 1 (10%) 1 (10%) 0.12
UDN (n = 10) 64 ± 6 6/4 2 (20%) 4.24 ± 0.43 1.42 ± 0.35 1.19 ± 0.16 2.44 ± 0.44 127 ± 13 82 ± 12 1 (10%) 2 (20%) 1 (10%) 0.34
Stroke (24 W)
LA (n = 10) 65 ± 7 6/4 1 (10%) 4.36 ± 0.27 1.56 ± 0.42 1.14 ± 0.15 2.43 ± 0.56 126 ± 15 88 ± 12 1 (10%) 2 (20%) 2 (20%) 0.87
SA (n = 9) 66 ± 6 4/5 1 (11%) 4.39 ± 0.59 1.44 ± 0.32 1.17 ± 0.12 2.39 ± 0.45 124 ± 13 83 ± 11 2 (22%) 2 (22%) 1 (11%) 0.23
CEmb (n = 10) 64 ± 5 5/5 1 (10%) 4.35 ± 0.49 1.37 ± 0.41 1.15 ± 0.16 2.50 ± 0.43 126 ± 15 85 ± 12 1 (10%) 1 (10%) 1 (10%) 0.13
UDN (n = 9) 65 ± 6 5/4 1 (11%) 429 ± 0.39 1.49 ± 0.29 1.19 ± 0.18 2.45 ± 0.45 125 ± 13 86 ± 11 1 (11%) 1 (11%) 1 (11%) 0.56
Stroke (48 W)
LA (n = 10) 64 ± 7 6/4 2 (20%) 4.46 ± 0.28 1.57 ± 0.42 1.15 ± 0.13 2.55 ± 0.43 127 ± 12 84 ± 12 1 (10%) 2 (20%) 2 (20%) 0.11
SA (n = 10) 66 ± 5 5/5 2 (20%) 4.35 ± 0.42 1.43 ± 0.32 1.17 ± 0.20 2.46 ± 0.53 123 ± 11 83 ± 10 2 (20%) 1 (10%) 1 (10%) 0.45
CEmb (n = 10) 65 ± 7 4/6 1 (10%) 4.37 ± 0.42 1.38 ± 0.41 1.23 ± 0.15 2.61 ± 0.53 125 ± 10 87 ± 14 1 (10%) 1 (10%) 1 (10%) 0.55
UDN (n = 9) 64 ± 8 5/4 1 (11%) 4.44 ± 0.32 1.42 ± 0.33 1.17 ± 0.18 2.65 ± 0.62 129 ± 13 87 ± 13 1 (11%) 1 (10%) 1 (10%) 0.87
Healthy outpatient
(n = 50)
64 ± 6 24/26 10 (20%) 4.52 ± 0.48 1.39 ± 0.40 1.15 ± 0.14 2.50 ± 0.62 125 ± 11 82 ± 11 5 (10%) 5 (10%) 6 (12%)
CHS, Characteristics; M/F, Male/female; CS, Current smoking; TC, total cholesterol (mmol/L); TG, total glyceride (mmol/L); HDL, high-density lipoprotein (mmol/L); LDL, low-densitlipoprotein (mmol/L); SBP, systolic
blood pressure (mmHg); DBP, diastolic blood pressure (mmHg); DM, diabetes mellitus; HT, Hypertension; HL, Hyperlipidaemia; LA, Large artery stroke; SA, Small artery stroke; CEmb, Cardioembolic stroke; UDN, stroke
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http://www.biomedcentral.com/1471-2377/13/178protects against dementia induced by chronic brain hy-
poperfusion via its anti-amyloidogenic effect in rats [14].
The involvement of miRNA in regulating the patho-
genesis associated with middle cerebral artery occlusion
(MCAo) in SD rats was first reported by Jeyaseelan
et al., which demonstrated that miR-30a-3p was down-
regulated in the 24-hour-reperfused MCAo rat brains
but was subsequently up-regulated during the 48-hour
reperfusion [15]. Recent studies indicate that miR-30
family regulates angiogenesis [16], and endothelium spe-
cific miRNA–miR-126 was down-regulated in young
stroke patients [17]. Moreover, the expression of LIN28B
and let-7 miRNA correlated with rs17065417 genotype
in neuroblastoma cell lines [18]. Let-7 activates Toll-
like receptor 7 that contributes to the spread of CNS
damage [19].
Acute myocardial ischemia and ischemic stroke have
similar pathophysiology, and our previous studies implied
that the plasma concentration of miRNAs can be potential
indicators of AMI [20-22]. Using the levels of circulating
miR-30a, miR-126 and let-7b at early phase of AMI, we
were able to define a score with a high sensitivity and spe-
cificity for the detection of AMI patients [21,22].
However, it is not clear whether miR-30a, miR-126
and let-7b are involved in ischemic stroke and specific-
ally, assosiation of their plasma levels and ischemic
stroke has not been reported. In the present study, weTable 2 Alterations in plasma miRNA levels in patients with is
STRO
24 h 1 w 4 w
miR-30a
LA Δct ± SD −4.42 ± 0.57 −4.12 ± 0.43 −4.53 ±
SA Δct ± SD −4.15 ± 0.43 −4.36 ± 0.18 −4.63 ±
CEmb Δct ± SD −4.79 ± 0.40 −4.71 ± 0.15 −5.26 ±
UND Δct ± SD −3.94 ± 0.32 −4.91 ± 0.28 −5.33 ±
p value 0.02 0.01 0.0
miR-126
LA Δct ± SD 4.51 ± 1.25 4.28 ± 1.13 3.95 ±
SA Δct ± SD 4.38 ± 1.12 4.16 ± 1.15 3.75 ±
CEmb Δct ± SD 4.57 ± 1.32 4.08 ± 0.98 3.86 ±
UND Δct ± SD 4.49 ± 1.08 4.12 ± 1.02 3.69 ±
p value 0.01 0.01 0.0
Let-7b
LA Δct ± SD −9.12 ± 1.25 −9.36 ± 1.06 −9.28 ±
SA Δct ± SD −13.98 ± 2.15 −14.18 ± 1.32 −13.46
CEmb Δct ± SD −14.36 ± 2.18 −14.78 ± 1.95 −14.12
UND Δct ± SD −14.23 ± 1.58 −14.97 ± 1.78 −14.67
p value 0.01 0.02 0.0
Δct value of miR-126, miR-30a and let-7b in ischemic stroke groups and healthy ad
Corresponding p values were calculated using the Independent-samples T test. HAassessed the hypothesis that circulating miR-30a, miR-
126 and let-7b might be useful for identifying and evalu-
ating ischemic stroke in humans.
Methods
Blood samples
Experiments were conducted in accordance with the
principles of Declaration of Helsinki. This study was ap-
proved by the Ethics Committee of Tongji Hospital.
Written informed consents were obtained from all the
participants and 247 blood samples (5 ml) were collected
from the ischemic stroke patients and healthy volunteers
at Tongji hospital from June 2009 to October 2009. The
study included first-ever stroke patients with cerebral
infarction. Diagnosis was based on the International Clas-
sification of Diseases, Ninth Revision as described previ-
ously [23]. Imaging studies were reviewed by experienced
neuroradiologists to confirm the diagnosis and identify
the stroke subtypes.
The ischemic stroke patients identified by World Health
Organization clinical criteria were further classified ac-
cording to TOAST classification, a) large-vessel athero-
sclerosis (LA, n = 51); b) small-vessel disease (SA, n = 48);
c) cardioembolism (CEmb, n = 50); d) undetermined cause
(UDN, n = 48) [17]. The patients’ functional status at the
time of blood sampling was evaluated with the modified
Rankin Scale (mRS). Exclusion criteria included otherchemic stroke compared to healthy controls
KE HA ΔCT ± SD
24 w 48 w
−6.18 ± 1.27
0.46 −4.65 ± 0.47 −6.02 ± 0.45
0.35 −4.38 ± 0.35 −5.97 ± 0.34
0.26 −5.7 ± 0.42 −6.12 ± 0.32
0.29 −4.29 ± 0.49 −6.05 ± 0.19
3 0.01 0.01
0.39 ± 0.012
1.05 3.45 ± 1.03 0.41 ± 0.023
1.12 2.95 ± 0.23 0.36 ± 0.013
0.89 3.15 ± 0.43 0.37 ± 0.021
0.97 1.98 ± 0.38 0.42 ± 0.032
2 0.03 0.01
−11.12 ± 2.16
1.34 −9.31 ± 1.13 −11.15 ± 1.22
± 1.45 −13.12 ± 1.42 −11.01 ± 1.08
± 1.53 −13.92 ± 1.67 −10.93 ± 1.52
± 1.36 −12.93 ± 1.76 −10.96 ± 1.63
1 0.01 0.01
ult. SD stands for the standard deviation of the average Δct of the group.
Δct ± SD stands for Δct ± SD of healthy adult.
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http://www.biomedcentral.com/1471-2377/13/178types of stroke (transient ischemic attack, subarachnoid
hemorrhage, embolic brain infarction, brain tumors, and
cerebrovascular malformation); severe systemic diseases,
for example, pulmonary fibrosis and endocrine and meta-
bolic diseases (except type 2 diabetes); inflammatory and
autoimmune diseases; and serious chronic diseases, for ex-
ample, hepatic cirrhosis and renal failure. Subjects with
cardioembolic stroke and documented atrial fibrillation
were also excluded from the study. In addition, healthy
volunteers meeting the same exclusion criteria as the cases
(negative imaging studies and no history of cerebrovascu-
lar disease, n = 50) were enrolled in our study.
This study was a cross-sectional study, stroke patients
were recruited at different time points after stoke, and
each time point was represented by a different set of pa-
tients. The blood samples of patients with ischemic
stroke were obtained at 24 h (within 24 h), 1 w (±24 h),
4 w (±24 h), 24 w (±48 h) and 48 w (±72 h) after the on-
set of symptoms. Plasma was isolated by centrifugation
and was maintained at −80°C until purification.
RNA purification
We extracted total RNA from plasma with TRIzol LS
Reagent as described previously [21].Figure 1 Levels of miR-30a in plasma samples of patients with ischemic
(A) The levels of miR-30a-LA at different time points; (B) The levels of miR-30a-
time points; (D) The levels of miR-30a-UDN at different time points (* vs. contromiRNA qRT-PCR
Two μg of total RNA were reverse transcribed by Tran-
script First-strand cDNA synthesis superMix (TransGen
Biotech, Beijing, China) according to the manufacturer’s
protocol. In brief, 50 μl reactions were incubated for
60 min at 42°C, 10 min at 70°C, and then preserved at
4°C.
qRT-PCR were performed using the Bulge-Loop™
miRNA qRT-PCR Detection Kit (Ribobio Co., Guangzhou,
China) and TransStart™ Green qPCR SuperMix (TransGen
Biotech, Beijing, China) according to the manufacturer’s
protocol with the Rotor-Gene 6000 system (Corbett Life
Science, Qiagen, Hilden, Germany). In brief, the reaction
was incubated at 95°C for 30 s, and followed by 40 cycles
of 95°C for 30 s, 60°C for 20 s, 70°C for 1 s. The relative
expression level of each miRNA was calculated using the
comparative CT method. MiRNA expression was normal-
ized to small nucleolar RNA U6.
Statistical analysis
Relative expression of miRNA was calculated using
2-ΔΔct method in duplicate experiments (change fold =
2−((Mean ΔCt Target)−(Mean ΔCt Calibrator))) [24]. MicroRNA
expression was normalized to endogenous control U6.stroke at 24 h, 1 w, 4 w, 24 w and 48 w after the onset of symptoms.
SA at different time points; (C) The levels of miR-30a-CEmb at different
l, p < 0.05).
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http://www.biomedcentral.com/1471-2377/13/178All values of miRNAs are expressed as mean ± SD. For
categorical variables, the Chi-Square test was used. Inde-
pendent samples t-test was used for 2-group compari-
sons. Differences were defined as statistically significant
at a value of p < 0.05.
A composite score (denoted as miRNA-score) was de-
fined to represent the cumulative levels of the miRNA
(miR-LA, miR-SA, miR-CEmb and miR-UDN) in the is-
chemic stroke group compared with the control group as
described previously [25]. The miRNA-score of each sam-
ple was calculated as the sum of the inverted-normalized
signals of the miRNA and adjusted by subtracting a con-
stant (the minimal score) so that the range of scores starts
at 0 [25]. The ability to distinguish the ischemic stroke
group and control group was characterized by the receiver
operating characteristic (ROC) curve, and the area under
the ROC curve (AUC) was calculated.
All statistical calculations were performed using SPSS
13.0 for Windows.
Results
Statistical analysis of patients’ characteristics
In our study, all patients suffered from ischemic stroke.
Age, gender, smoking history, total triglyceride, total
cholesterol, HDL, LDL, systolic blood pressure, diastolicFigure 2 Levels of miR-126 in plasma samples of patients with ischemic
(A) The levels of miR-126-LA at different time points; (B) The levels of miR-126-
time points; (D) The levels of miR-126-UDN at different time points (* vs. controblood pressure, and disease history were recorded. There
were no significant differences among ischemic stroke
groups and control group (p > 0.05). Details are shown
in Table 1.
MiRNAs plasma levels in ischemic stroke patients and
healthy volunteers
Using qRT-PCR assays, we measured the circulating
levels of miR-30a, miR-126 and let-7b in ischemic stroke
patients and healthy controls. Results are summarized in
Table 2, Figures 1,2,3 and Additional file 1: Figure S1–S3.
There were no significant differences among plasma miR-
NAs collected from patients and control at 48 w but it was
found that circulating miR-30a and miR-126 were down-
regulated in ischemic stroke patients at 24 h, 1 w, 4 w and
24 w. Plasma levels of miR-30a in all subtypes of ischemic
stroke patients’ were 45%-79% lower than the controls at
24 h, 1 w, 4 w and 24 w (Figure 1). Plasma levels of miR-
126 subtypes of ischemic stroke patients were 85%-98%
lower than the healthy controls at 24 h, 1 w, 4 w and 24 w
(Figure 2).
Interestingly, our data showed that the expression pat-
tern of circulating let-7b in ischemic stroke patients with
large-vessel atherosclerosis were different from patients
with other subtypes. Specifically, plasma levels of let-7bstroke at 24 h, 1 w, 4 w, 24 w and 48 w after the onset of symptoms.
SA at different time points; (C) The levels of miR-126-CEmb at different
l, p < 0.05).
Figure 3 Levels of let-7b in plasma samples of patients with ischemic stroke at 24 h, 1 w, 4 w, 24 w and 48 w after the onset of symptoms.
(A) The levels of let-7b-LA at different time points; (B) The levels of let-7b-SA at different time points; (C) The levels of let-7b-CEmb at different
time points; (D) The levels of let-7b-UDN at different time points (* vs. control, p < 0.05).
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http://www.biomedcentral.com/1471-2377/13/178from ischemic stroke patients with large-vessel athe-
rosclerosis (let-7b-LA) were 70%-75% lower than in healthy
controls at 24 h, 1 w, 4 w and 24 w (Figure 3A). However,
it was highly expressed in other subtypes of ischemic stroke
patients (let-7b-SA, let-7b-CEmb and let-7b-UDN) at
24 h, 1 w, 4 w and 24 w exhibiting 3.51-14.42 fold increase
(Figure 3B-D).
Moreover, circulating levels of these miRNAs were also
detected in blood samples from hemorrhagic stroke pa-
tients (Additional file 1: Figure S4). The results showed
that the circulating levels of the three miRNAs did not
change at the different time points examined.Specifity and sensitivity of miRNAs
Since the expressions of miRNAs may be affected by
both technical and biological variation, we combined the
levels of each miRNAs from different subtypes at the
same time point into a single score to increase the signal
to noise ratio. A miR-score represents the cumulative
level of the miRNA (miR-LA, miR-SA, miR-CEmb and
miR-UDN) for the comparison between ischemic stroke
group and control group, which was described in the
methods section. The miR-scores distinguished the is-
chemic stroke patients and the controls clearly (Table 3).The median score of miR-30a was 2.66, 2.37, 2.39 and
2.39 in stroke group and 1.30, 1.34, 1.35 and 1.34 in the
control group at 24 h, 1 w, 4 w and 24 w, respectively
(Figure 4A-D). The ability of the miR-30a-score to dif-
ferentiate the stroke group from the control group was
revealed further by the ROC curve with an AUC of 0.91
(95% confidence interval (CI) = 0.869-0.979), 0.91 (95%
CI = 0.848-0.971), 0.92 (95% CI = 0.856-0.976) and 0.93
(95% CI = 0.875-0.984) at 24 h, 1 w, 4 w and 24 w, respect-
ively. Using the optimal cutoff values of 1.675, 1.75, 1.67
and 1.665 for the diagnosis of stroke, we obtained a sensi-
tivity of 94%, 93%, 90% and 92% and a specificity of 80%,
84%, 84% and 84% at 24 h, 1 w, 4 w and 24 w, respectively
(Figure 4E-H).
When a comparison was made between the stroke pa-
tients and the healthy controls, the median score of
miR-126 at 24 h, 1 w, 4 w and 24 w was 2.54, 2.52, 2.52
and 2.54, respectively in the stroke group, compared with
1.33, 1.35, 1.40 and 1.39 in the control group, respectively
(Figure 5A-D). And the ROC curves with an AUC were
0.92 (95% CI = 0.871-0.978), 0.94 (95% CI = 0.895-0.985),
0.93 (95% CI = 0.878-0.982) and 0.92 (95% CI = 0.864-
0.977). Using the threshold score of 1.75, 1.875, 1.845 and
1.77, the sensitivity of miR-126-score for the diagnosis of
stroke was 92%, 90%, 92% and 92%, and the specificity
Table 3 Areas under the receiver operating characteristic curve and predictive value of three candidate miRNAs
95% CI AUC Cut-off point Specificity (%) Sensitivity (%)
miR-30a
24 h 0.869–0.979 0.91 1.675 94 80
1 W 0.848–0.971 0.91 1.75 93 84
4 W 0.856–0.976 0.92 1.67 90 84
24 W 0.875–0.984 0.93 1.665 92 84
miR-126
24 h 0.871–0.978 0.92 1.75 92 84
1 W 0.895–0.985 0.94 1.875 90 86
4 W 0.878–0.982 0.93 1.845 92 84
24 W 0.864–0.977 0.92 1.77 92 82
Let-7b
24 h 0.879–0.980 0.93 1.675 92 84
1 W 0.866–0.98 0.92 1.665 90 84
4 W 0.858–0.98 0.92 1.66 92 86
24 W 0.849–0.97 0.91 1.605 89 80
Long et al. BMC Neurology 2013, 13:178 Page 7 of 10
http://www.biomedcentral.com/1471-2377/13/178was 84%, 86%, 84% and 82% at 24 h, 1 w, 4 w and 24 w,
respectively. (Figure 5E-H).
Finally, the median score of let-7b was 2.33, 2.26, 2.22
and 2.23 in the stroke group, and 1.36, 1.35, 1.343 and
1.34 in the control group at 24 h, 1 w, 4 w and 24 w, re-
spectively (Figure 6A-D). The ability of the let-7b-score to
distinguish stroke group from control group was shown
by the ROC curve with an AUC of 0.93 (95% CI = 0.879-
0.980), 0.92 (95% CI = 0.866-0.98), 0.92 (95% CI = 0.858-
0.98) and 0.91 (95% CI = 0.849-0.97). By using a thresholdFigure 4 Discrimination between ischemic stroke and control group at 2
score). (A-D) The composite miR-30a-score was shown as median values
of the composite miRNA-score.score of 1.675, 1.665, 1.66 and 1.605, above which patients
were predicted to belong to the stroke group, we achieved
a sensitivity of 92%, 90%, 92% and 89%, and a specificity
of 84%, 84%, 86% and 80% for identification of ischemic
stroke patients at the above mentioned time points.
(Figure 6E-H).
Discussion
At present, the diagnosis of stroke depends on clinical
examination and various neuro-imaging techniques.4 h, 1 w, 4 w, 24 w using the composite miRNA score (miR-30a-
in different groups. (E-H) ROC curve analyzed the diagnostic value
Figure 5 Discrimination between ischemic stroke and control group at 24 h, 1 w, 4 w, 24 w using the composite miRNA score
(miR-126-score). (A-D) The composite miR-126-score was shown as median values in different groups. (E-H) ROC curve analyzed the diagnostic
value of the composite miRNA-score.
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http://www.biomedcentral.com/1471-2377/13/178However, there are no reliable circulating biomarkers for
acute ischemic stroke risk prediction, diagnosis and out-
come prediction [26,27]. It was reported that circulatory
microRNA-145 expression is increased in cerebral is-
chemia, but the patient sample collection time was not
mentioned [28]. In previous studies, we identified that
circulating miRNAs were associated with human AMI
[20-22]. In the present study, we found that the levelsFigure 6 Discrimination between ischemic stroke and control group a
(let-7b-score). (A-D) The composite let-7b-score was shown as median va
of the composite miRNA-score.of circulating miR-30a, miR-126 and let-7b differed be-
tween the ischemic stroke and the control group. The
most important findings are that the circulating levels
of miR-30a, miR-126 and let-7b (let-7b-LA) were de-
creased and let-7b (let-7b-SA, let-7b-CEmb and let-7b-
UDN) were increased in ischemic stroke patients than
in the control group at 24 h, 1 w, 4 w, 24 w but not at
48 w.t 24 h, 1 w, 4 w, 24 w using the composite miRNA score
lues in different groups. (E-H) ROC curve analyzed the diagnostic value
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http://www.biomedcentral.com/1471-2377/13/178It is widely believed that miRNAs released from dam-
aged cells or circulating cells lead to increased plasma
miRNA expressions [29]. However, the exact reason for
miRNA levels decrease after ischemic stroke is not clear.
We suspect that 1) circulating miRNAs are released by
normal cells, and they are decreased when the cells are
injured or cell density gets lowered; 2) circulating miR-
NAs are rapidly removed following their release into the
circulation. However, further experiments are needed to
explore these mechanisms.
To avoid possible bias from patients’ selection, individ-
uals with similar age, gender, total cholesterol, HDL, LDL,
triglyceride, systolic and diastolic blood pressures, diabetes
and smoking status were recruited in the present study.
And the statistical analysis implied that miR-30a, miR-126
and let-7b levels in plasma were not associated with those
characteristics. These data further suggested that miR-30a,
miR-126 and let-7b may be potential biomarkers for ische-
mic stroke.
The next questions are whether circulating levels of
the plasma miR-30a, miR-126 and let-7b concentrations
has any clinical significance and whether miRNAs might
be a useful biomarker with diagnostic or prognostic roles
in ischemic stroke patients. Using the levels of the three
miRNA, we defined a score with a high specificity and
sensitivity for the detection of ischemic stroke patients
relative to control group. As a result, our data clearly
verified the hypothesis that miR-30a, miR-126 and let-7b
may be useful biomarkers for identifying the ischemic
stroke.
Through bio-informatic analysis, we found that stroke
related genes RhoB and beclin-1 might be the targets of
miR-30a. Previously, miR-126 was reported to participate
in atherosclerosis regulation by targeting 3′ UTR of
VCAM-1 [30]. And let-7 family may be involved in stroke
via inflammatory response [31]. It is important to consider
the mechanisms by which these circulating miRNAs play
a role in local pathophysiological processes. It has been
shown that cell to cell communication can be mediated by
exosomes containing miRNAs [32]. Recent data showed
that miRNAs in extracellular vesicles facilitate communi-
cation between tumor cells and endothelial cells, and
endothelial cells and smooth muscle cells, suggesting that
stroke-related circulating miRNAs may be functional in
the similar pattern [33,34].
It must be pointed out that this study has relatively
small sample size and the results should be further va-
lidated in larger sample studies to confirm the role of
miR-30a, miR-126 and let-7b levels as biomarkers for
ischemic stroke in the future. Also, the sensitivity and
specificity should be analyzed in larger, long term
studies. And the reasons behind varying expressions of
let-7b among various types of ischemic stroke deserves
further investigation.A cross-sectional study is an observational study in
which exposure and outcomes are determined simultan-
eously for each subject. It is often described as taking a
“snapshot” of a group of individuals. Cross-sectional
studies are most appropriate for screening hypotheses
because they require a relatively shorter time commit-
ment and fewer resources to conduct [35]. However,
there are some limitations of our study. Firstly, although
we found that there is an association between circulating
miRNAs expression and ischemic stroke, there is generally
no direct evidence that the miRNAs caused the outcome.
Secondly, ischemic stroke is not an inherent trait but one
that developes over time, the causality of circulating
miRNA is unclear. Finally, a follow-up study may be more
helpful to better understand the association between cir-
culating miRNAs expression and ischemic stroke.
Conclusions
In summary, our data demonstrated a significant change
in the circulating levels of miR-30a, miR-126 and let-7b
in patients with ischemic stroke suggesting that miR-30a,
miR-126 and let-7b might be the potential biomarkers for
the diagnosis of ischemic stroke.
Additional file
Additional file 1: Figure S1. Levels of miR-30a in plasma samples of
patients with ischemic stroke at 24 h, 1 w, 4 w, 24 w and 48 w after the
onset of symptoms displayed by scatter. (A) The levels of miR-30a-LA at
different time points; (B) The levels of miR-30a-SA at different time points;
(C) The levels of miR-30a-CEmb at different time points; (D) The levels of
miR-30a-UDN at different time points (* vs. control, p<0.05). Figure S2.
Levels of miR-126 in plasma samples of patients with ischemic stroke at
24 h, 1 w, 4 w, 24 w and 48 w after the onset of symptoms displayed by
scatter. (A) The levels of miR-126-LA at different time points; (B) The
levels of miR-126-SA at different time points; (C) The levels of miR-126-
CEmb at different time points; (D) The levels of miR-126-UDN at different
time points (* vs. control, p<0.05). Figure S3. Levels of let-7b in plasma
samples of patients with ischemic stroke at 24 h, 1 w, 4 w, 24 w and
48 w after the onset of symptoms displayed by scatter. (A) The levels of
let-7b-LA at different time points; (B) The levels of let-7b-SA at different
time points; (C) The levels of let-7b-CEmb at different time points; (D)
The levels of let-7b-UDN at different time points (* vs. control, p<0.05).
Figure S4. Levels of miRNAs in plasma samples of patients with ischemic
stroke at 24 h, 1 w, 4 w, 24 w and 48 w after the onset of symptoms. (A)
The levels of miR-30a at different time points; (B) The levels of miR-126 at
different time points; (C) The levels of let-7b at different time points.
Table S1. Patients’ functional status at the time of blood sampling.
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